Concurrent Opioid and Benzodiazepine in a High-Risk Patient
A 58-year-old woman with chronic neck pain and anxiety takes oxycodone 30 mg twice daily (90 MME/day), alprazolam 1 mg three times daily, and zolpidem 10 mg nightly. She has obesity (BMI 34), obstructive sleep apnea, and depression; she does not use CPAP. She lives alone and has had one emergency department visit for excessive sedation. Today she requests an early refill because she "lost" a week of pills. The prescription drug monitoring program shows two opioid prescribers and one benzodiazepine prescriber. A urine drug test is negative for oxycodone and positive for alprazolam.
1. Identify the highest-risk elements and explain how you would respond in the office today.
Read the worked answer
The highest-risk elements are concurrent opioid, benzodiazepine, and z-drug use; untreated OSA; a prior sedation visit; possible misuse suggested by an early refill and lost pills; multiple prescribers; and a negative urine test for oxycodone, which suggests nonuse, diversion, or rapid metabolism. I would not provide an early refill. I would assess for overdose risk, sedation, and withdrawal; provide naloxone; check the PDMP; and obtain a confirmatory urine test. I would express concern rather than accuse, explain that continuing the current regimen is unsafe, and make a same-day safety plan.
2. Outline a safe tapering and risk-mitigation plan, including which medications to change first and how to prevent withdrawal and overdose.
Read the worked answer
Do not stop any medication abruptly. Prioritize the benzodiazepine and z-drug taper because of the overdose risk with opioids and untreated OSA; reduce alprazolam slowly, such as 5–10% every 2–4 weeks, and stop zolpidem with CBT-I. Taper oxycodone gradually, or transition to buprenorphine if opioid use disorder is diagnosed. Treat OSA with CPAP and refer to sleep medicine. Provide naloxone and education to her and a family member. Coordinate mental health treatment. Monitor for withdrawal and suicide risk. If opioid use disorder is present, offer buprenorphine/naloxone.
3. What practice-management and documentation steps would you take, including communication with other prescribers and controlled-substance agreement?
Read the worked answer
Document risk stratification, informed consent, PDMP review, urine drug testing, and a single-prescriber agreement. Communicate in writing with the other opioid and benzodiazepine prescribers and designate one prescriber for controlled substances. Use pill counts and frequent visits. Refer to addiction medicine or psychiatry as indicated. Follow state prescribing rules and clinic policy. Document that early refills were declined and why, along with the safety plan. This creates a defensible record and reduces the chance of duplicated prescribing.